MannKind Launches Pediatric Trial for Inhaled Insulin in Type 1 Diabetes

Event summary

  • First patient enrolled in INHALE-1ST study evaluating Afrezza® for pediatric type 1 diabetes.
  • Study will assess safety and efficacy of Afrezza in combination with basal insulin in 10-17 year-olds.
  • Trial involves ~100 patients across 10 U.S. clinical sites, with primary endpoint measuring CGM time-in-range.
  • FDA review of Afrezza’s pediatric indication ongoing, with PDUFA target action date of May 29, 2026.

The big picture

MannKind’s INHALE-1ST trial represents a strategic push into pediatric diabetes care, an underserved segment where needle-free insulin could offer significant advantages. If successful, this could expand Afrezza’s market potential beyond adults, aligning with broader industry trends toward patient-centric, non-invasive diabetes treatments. The FDA’s pending decision on the pediatric indication will be a key inflection point for MannKind’s growth trajectory.

What we're watching

Regulatory Approval
Whether the FDA will approve Afrezza for pediatric use by the May 2026 PDUFA date, potentially creating a first needle-free insulin option for children.
Clinical Outcomes
How the INHALE-1ST trial results will impact adoption of inhaled insulin in pediatric diabetes management.
Market Differentiation
The pace at which MannKind can position Afrezza as a preferred alternative to traditional insulin injections in the pediatric market.